Torren Management’s BioAge Labs BIOA Stock Holding History

Torren Management’s Portfolio BIOA Stock Details BIOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.22K	Hold	213	–	–	﹤0.01%	329
2026 Q1	$3.73K	Hold	213	–	–	﹤0.01%	383
2025 Q4	$2.82K	Buy	+213	New	+$1.89K	﹤0.01%	1000

Other funds holding BIOA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ACM

Alessandra Capital Management Torrance, California $141M AUM

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Torren Management's BIOA Position: Q2 2026 in Review

Torren Management held its BioAge Labs (BIOA) position steady in Q2 2026 at 213 shares worth $5.22K. The position accounts for ﹤0.01% of the portfolio, ranked #329.

Torren Management first reported a position in BIOA in Q4 2025 and has held it in 3 quarters since. 37 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

Torren Management held 213 shares of BioAge Labs worth $5.22K as of Q2 2026.
Torren Management left its BioAge Labs share count unchanged in Q2 2026.
BioAge Labs made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #329 holding.
Torren Management first reported a position in BioAge Labs in Q4 2025 and has held it in 3 quarters since.
37 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.